Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × Adrenergic beta-Antagonists × Clear all

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Paclitaxel 486 Carboplatin 431 Gemcitabine 389 Docetaxel 383 Cisplatin 356 pembrolizumab 336 Bevacizumab 334 Nivolumab 259 Pemetrexed 242 Capecitabine 221 Fluorouracil 211 Dexamethasone 211 Rituximab 202 Trastuzumab 193 Cyclophosphamide 187 Oxaliplatin 160 Erlotinib Hydrochloride 146 atezolizumab 145 Ipilimumab 145 Prednisone 144 Cetuximab 141 Irinotecan 138 Leucovorin 130 Doxorubicin 129 Sorafenib 120 Lenalidomide 117 Bortezomib 117 Sunitinib 107 Everolimus 93 Radiotherapy 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

1,165,781 enrolled

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡